CD Antigen Cancer Therapy Market By Target Antigen (CD38, CD19, CD20, BCMA/CD269, CD22, CD30, CD33, CD70 and Other Targets); By Therapeutic Modality (Monoclonal Antibodies, CAR-T Cell Therapies, Antibody-Drug Conjugates, Bispecific Antibodies and BiTEs, Radioimmunotherapies and Other Modalities); By Cancer Application (Multiple Myeloma, B-Cell Lymphomas, Leukemias, Hodgkin Lymphoma and Other Cancers); By End User (Hospitals and Comprehensive Cancer Centers, Specialty Hematology and Cell-Therapy Centers, Research and Academic Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

CD Antigen Cancer Therapy Market: Antibody Scale Meets CAR-T and Bispecific Growth – (Updated On: 22nd-Sep-2026)

The Global CD Antigen Cancer Therapy Market was valued at USD 33.0 billion in 2025 and is projected to reach USD 66.3 billion by 2032, expanding at a CAGR of 10.85% during 2026–2032. CD antigen cancer therapies are targeted immunotherapies that identify and bind to specific Cluster of Differentiation (CD) markers expressed on cancer cells, particularly in hematological malignancies, enabling precise immune-mediated cancer treatment.

 

CD antigens are cell surface proteins used to identify and classify immune and cancer cells, with overexpressed or uniquely expressed markers serving as therapeutic targets. Major treatment approaches include monoclonal antibodies (mAbs), Chimeric Antigen Receptor (CAR)-T cell therapies, antibody-drug conjugates (ADCs), and bispecific T-cell engagers (BiTEs).

 

Key CD targets driving market growth include CD19, targeted in therapies for B-cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL); CD20, targeted by monoclonal antibodies such as Rituximab for B-cell malignancies; and CD38, targeted by therapies such as Daratumumab for multiple myeloma. CAR-T cell therapies targeting CD19 and BCMA have become major growth contributors, particularly for patients with relapsed or refractory hematological cancers.

 

The increasing burden of blood cancers is a significant market driver, with leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, and multiple myeloma collectively contributing to more than 1.3 million new cases annually worldwide, creating substantial demand for advanced targeted therapies. Additionally, monoclonal antibody-based treatments have achieved broad clinical adoption, with the American Cancer Society estimating that approximately 90,000 U.S. patients received naked or conjugated monoclonal antibody therapies in recent baseline tracking years.

 

Advancements in CAR-T technology, expansion of FDA-approved CD19- and BCMA-directed CAR-T therapies in the U.S., increasing survival rates, and wider availability of targeted immunotherapies are accelerating market growth. Overall, rising cancer prevalence, improved treatment outcomes, increasing antigen coverage, and the transition of CD antigen therapies from heavily pre-treated patients toward earlier treatment settings are expected to expand the addressable patient population and drive long-term market development.

 

Key Report Takeaways—CD38 Leads Revenue as BCMA and Bispecifics Accelerate

By Target Antigen

• CD38 holds the leading 32% share, representing USD 10.560 billion in 2025 revenue, and is projected to expand at a CAGR of 9.50% during 2026–2032.

• CD19 accounts for a 25% share, equivalent to USD 8.250 billion in 2025 revenue, and is expected to grow at a CAGR of 11.50% during 2026–2032.

• CD20 represents a 21% share, generating USD 6.930 billion in 2025 revenue, and is projected to expand at a CAGR of 7.80% during 2026–2032.

• BCMA/CD269 holds a 13% share, corresponding to USD 4.290 billion in 2025 revenue, and is projected to record the fastest CAGR of 16.80% during 2026–2032.

• CD22, CD30, CD33, CD70, and Other Targets collectively account for a 9% share, equivalent to USD 2.970 billion in 2025 revenue, and are expected to grow at a CAGR of 11.20% during 2026–2032.

 

By Therapeutic Modality

• Monoclonal Antibodies command the largest 52% share, generating USD 17.160 billion in 2025 revenue, and are projected to expand at a CAGR of 8.50% during 2026–2032.

• CAR-T Cell Therapies account for a 21% share, equivalent to USD 6.930 billion in 2025 revenue, and are expected to grow at a CAGR of 14.60% during 2026–2032.

• Antibody-Drug Conjugates represent a 15% share, corresponding to USD 4.950 billion in 2025 revenue, and are projected to expand at a CAGR of 11.20% during 2026–2032.

• Bispecific Antibodies and BiTEs hold a 9% share, generating USD 2.970 billion in 2025 revenue, and are projected to record the fastest CAGR of 17.80% during 2026–2032.

• Radioimmunotherapies, Immunotoxins, and Other Modalities collectively account for a 3% share, equivalent to USD 0.990 billion in 2025 revenue, and are expected to grow at a CAGR of 7.00% during 2026–2032.

 

By Cancer Application

• Multiple Myeloma holds the largest 36% share, representing USD 11.880 billion in 2025 revenue, and is projected to record the fastest CAGR of 12.00% during 2026–2032.

• B-Cell Lymphomas account for a 34% share, equivalent to USD 11.220 billion in 2025 revenue, and are expected to expand at a CAGR of 9.40% during 2026–2032.

• Leukemias represent a 23% share, generating USD 7.590 billion in 2025 revenue, and are projected to grow at a CAGR of 10.70% during 2026–2032.

• Hodgkin Lymphoma and Other Cancers collectively hold a 7% share, corresponding to USD 2.310 billion in 2025 revenue, and are expected to expand at a CAGR of 8.20% during 2026–2032.

 

By End User

• Hospitals and Comprehensive Cancer Centers hold a dominant 61% share, representing USD 20.130 billion in 2025 revenue, and are projected to expand at a CAGR of 9.80% during 2026–2032.

• Specialty Hematology and Cell-Therapy Centers account for a 28% share, equivalent to USD 9.240 billion in 2025 revenue, and are projected to record the fastest CAGR of 13.20% during 2026–2032.

• Research and Academic Institutes represent an 11% share, corresponding to USD 3.630 billion in 2025 revenue, and are expected to grow at a CAGR of 9.00% during 2026–2032.

 

By Geography

• North America holds the leading 46% share, representing USD 15.180 billion in 2025 revenue, and is projected to expand at a CAGR of 9.70% during 2026–2032.

• Europe accounts for a 26% share, equivalent to USD 8.580 billion in 2025 revenue, and is expected to grow at a CAGR of 10.40% during 2026–2032.

• Asia-Pacific represents a 22% share, corresponding to USD 7.260 billion in 2025 revenue, and is projected to record the fastest regional CAGR of 14.20% during 2026–2032.

• Latin America contributes a 4% share, equivalent to USD 1.320 billion in 2025 revenue, and is expected to expand at a CAGR of 9.10% during 2026–2032.

• Middle East & Africa accounts for a 2% share, representing USD 0.660 billion in 2025 revenue, and is projected to grow at a CAGR of 7.30% during 2026–2032.

 

Segment Leadership—Established Antibodies Fund the Shift Toward Next-Generation Platforms

By Target Antigen: CD38 Anchors Revenue While BCMA Transforms Growth

Revenue Leader—CD38

CD38 emerged as the leading segment, capturing 32% of the market share with USD 10.560 billion in revenue in 2025, and is anticipated to grow at a CAGR of 9.50% during 2026–2032. CD38 is a multifunctional cell-surface glycoprotein and ectoenzyme highly expressed on malignant plasma cells, making it a key target for therapies such as Daratumumab and Isatuximab in multiple myeloma. Anti-CD38 therapies promote tumor cell destruction through immune mechanisms, reduce immunosuppressive cells, enhance T-cell and NK-cell activity, and are also being explored in emerging CAR-T cell therapies for hematological malignancies.

Growth Leader—BCMA/CD269

BCMA/CD269 represented a 13% share of the market, accounting for USD 4.290 billion in 2025 revenue, and is projected to register the fastest CAGR of 16.80% during 2026–2032. B-cell maturation antigen (BCMA), also known as CD269 or TNFRSF17, is a tumor-associated receptor highly expressed on malignant plasma cells in multiple myeloma, making it a key immunotherapy target. Its selective expression enables advanced treatments, including BCMA-directed CAR-T therapies, bispecific antibodies, and antibody-drug conjugates (ADCs) that enhance targeted cancer cell destruction.

 

By Therapeutic Modality: Antibody Scale Meets Off-the-Shelf Innovation

Revenue Leader—Monoclonal Antibodies

Monoclonal antibodies represented the leading segment, accounting for 52% of the CD Antigen Cancer Therapy Market, equivalent to USD 17.160 billion in 2025 revenue, and are expected to expand at a CAGR of 8.50% from 2026 to 2032. Monoclonal antibodies (mAbs) targeting CD antigens are precision cancer therapies that recognize specific tumor surface markers, enabling immune activation, targeted drug delivery, or T-cell engagement. These antibodies bind CD proteins such as CD20, CD30, CD33, and CD52, which are commonly expressed in blood cancers.

Growth Leader—Bispecific Antibodies and BiTEs

Bispecific antibodies (BsAbs) and BiTEs (Bispecific T-cell engagers) accounted for a 9% market share, representing USD 2.970 billion in 2025 revenue, and are expected to expand at the fastest CAGR of 17.80% during 2026–2032. These immune-based therapies function as molecular connectors by linking cancer cells with T cells, enabling targeted immune activation. BsAbs and BiTEs bind tumor antigens such as CD19, BCMA, or DLL3 while engaging CD3 on T cells, forming an artificial immune synapse that triggers cancer-cell destruction through cytotoxic mechanisms. BsAbs generally offer longer half-life, whereas BiTEs provide strong tumor penetration but require frequent dosing. Their off-the-shelf availability compared with CAR-T therapies is accelerating adoption in hematological cancers, although management of cytokine release syndrome and neurotoxicity remains a key clinical challenge.

 

By Cancer Application: Multiple Myeloma Leads Across Scale and Expansion

Revenue Leader—Multiple Myeloma

Multiple myeloma generated the largest application revenue, accounting for a 36% share and USD 11.880 billion in 2025, supported by a 12.00% CAGR during 2026–2032. The disease has the broadest concentration of commercially successful CD-directed products, including CD38 antibodies, BCMA CAR-T therapies, and BCMA/CD3 bispecific antibodies. Treatment frequently involves sequential regimens because most patients eventually relapse, creating recurring demand across induction, maintenance, and later-line therapy. The availability of several target classes also allows physicians to change mechanisms after resistance develops.

Growth Leader—Multiple Myeloma

Multiple myeloma is also the fastest-growing cancer application, with a projected 12.00% CAGR. Its growth position reflects the rapid expansion of BCMA-directed treatments beyond heavily pretreated patients. The U.S. treatment landscape already includes two BCMA-targeted CAR-T products and multiple BCMA-targeted bispecific antibodies. New trials are evaluating these therapies in earlier disease stages and in treatment combinations, which could substantially enlarge the eligible population. Competition is also extending toward dual-target constructs designed to reduce BCMA antigen escape and improve response durability.

 

By End User: Comprehensive Hospitals Lead as Dedicated Cell-Therapy Capacity Expands

Revenue Leader—Hospitals and Comprehensive Cancer Centers

Hospitals and comprehensive cancer centers dominated the CD antigen cancer therapy market, accounting for a 61% share valued at USD 20.130 billion in 2025, and are expected to grow at a CAGR of 9.80% from 2026–2032. These facilities serve as the primary hubs for administering advanced therapies such as CAR-T cells and CD-targeted monoclonal antibodies, supported by specialized treatment units, multidisciplinary oncology teams, immune-reaction management capabilities, and precision diagnostics including flow cytometry and genomic testing for patient selection.

Growth Leader—Specialty Hematology and Cell-Therapy Centers

Specialty hematology and cell-therapy centers accounted for a 28% share, equivalent to USD 9.240 billion in 2025 revenue, and are expected to record the fastest CAGR of 13.20% during 2026–2032. These centers are expanding as manufacturers add certified treatment locations and healthcare systems create dedicated cellular-therapy units. Their focused clinical teams can manage patient selection, apheresis, bridging therapy, infusion scheduling, and long-term follow-up more efficiently. Growth will also benefit from outpatient-compatible bispecific antibodies and improved toxicity-management protocols that reduce dependence on extended hospitalization.

 

By Geography: North American Leadership Meets Asia-Pacific Scale-Up

Revenue-Leading Region—North America

North America dominated the CD antigen cancer therapy market with a 46% share, generating USD 15.180 billion in 2025 revenue, and is projected to grow at a CAGR of 9.70% during 2026–2032. The region’s leadership is supported by early adoption of CD-targeted treatment platforms, including CD19-directed CAR-T cell therapies for B-cell malignancies, CD20-targeted monoclonal antibodies for lymphoma, and BCMA-directed therapies for multiple myeloma. The presence of leading cell therapy centers, advanced manufacturing capabilities, extensive clinical trial activity, and favorable regulatory pathways for antigen-specific therapies has accelerated the adoption of CD antigen-based treatments. Increasing use of personalized immunotherapies across hematological cancers continues to strengthen regional market expansion.

Fastest-Growing Region—Asia-Pacific

Asia-Pacific accounted for a 22% share of the global CD antigen cancer therapy market, generating USD 7.260 billion in 2025, and is projected to register the fastest regional CAGR of 14.20% during 2026–2032. Growth is driven by increasing diagnosis of hematological malignancies, expanding access to CD antigen-targeted therapies, and rising adoption of CAR-T cell therapies targeting CD19 and BCMA antigens. Countries across the region are strengthening domestic cell therapy capabilities to reduce dependence on imported CAR-T and monoclonal antibody treatments, while biotechnology companies are developing locally manufactured CD-targeted therapies. Increasing clinical trials, regulatory support for advanced therapies, and growing availability of antigen-specific treatments for leukemia, lymphoma, and multiple myeloma are expected to accelerate market expansion in Asia-Pacific.

 

Market Adoption Barriers—Cost, Toxicity, Resistance, and Capacity Constrain Scale

CAR-T Manufacturing Timelines Restrict Patient Access

Autologous CAR-T therapy requires patient screening, T-cell collection, genetic modification, cell expansion, quality testing, lymphodepleting chemotherapy, infusion, and post-treatment monitoring. The complete manufacturing process generally takes three to five weeks, during which patients with rapidly progressing disease may require bridging therapy or become medically ineligible for infusion. Specialized manufacturing, cold-chain logistics, hospitalization, and toxicity management further increase the total treatment cost beyond the product price. These requirements limit commercial deployment to well-funded healthcare systems and specialized treatment centers.

Toxicity Management Concentrates Treatment in Experienced Centers

CAR-T therapies and bispecific antibodies can cause cytokine-release syndrome, immune effector cell-associated neurotoxicity syndrome, severe infections, prolonged cytopenias, and B-cell depletion. These complications require step-up dosing, continuous monitoring, intensive-care availability, and access to treatments such as tocilizumab and corticosteroids. The FDA also requires boxed warnings for secondary T-cell malignancies following BCMA- or CD19-directed autologous CAR-T therapy. European regulators evaluated 38 secondary T-cell malignancies among approximately 42,500 treated patients, with seven cases linked to CAR-T products. These safety requirements increase delivery costs and restrict treatment outside experienced oncology centers.

Antigen Escape Challenges Response Durability

CD-targeted therapies depend on continued expression of the selected antigen. Cancer cells may reduce, alter, or completely lose CD19, CD20, CD38, or BCMA expression after treatment, allowing antigen-negative cells to survive and cause relapse. Repeated exposure can also select resistant tumor populations or reduce target density below the level required for effective immune recognition. Dual-target CAR-T constructs such as CD19/CD22 and sequential targeting strategies are being developed to address this problem, but they add manufacturing complexity, development costs, and additional regulatory requirements.

Solid-Tumor Barriers Limit Addressable Expansion

CD antigen therapies have achieved their strongest clinical results in leukemia, lymphoma, and multiple myeloma because malignant blood cells generally express identifiable surface targets and remain accessible to circulating immune cells. Solid tumors present greater antigen heterogeneity, poor T-cell penetration, physical stromal barriers, and an immunosuppressive tumor microenvironment. Many solid-tumor antigens are also expressed on healthy tissues, increasing the risk of on-target, off-tumor toxicity. As a result, most commercial CD-targeted CAR-T and bispecific therapies remain concentrated in hematologic cancers, limiting near-term expansion into the much larger solid-tumor population.

Certified-Center Constraints Create Geographic Access Gaps

CAR-T administration remains concentrated in certified hospitals and comprehensive cancer centers with apheresis units, cell-processing capabilities, specialized pharmacies, intensive-care support, and trained hematology teams. Patients located far from these centers may face travel, accommodation, caregiver, and follow-up costs in addition to treatment expenses. Although the FDA removed Risk Evaluation and Mitigation Strategy requirements for approved CAR-T products in 2025, boxed warnings and post-infusion monitoring requirements remain. The regulatory change reduces administrative burden but does not eliminate the infrastructure needed for safe treatment

Biosimilars Intensify Pricing Pressure on Mature Antibodies

Mature CD20-directed monoclonal antibodies face increasing competition from rituximab biosimilars, which can reduce treatment costs but place downward pressure on branded product revenue. Similar pricing pressure may emerge as additional antibody patents expire and healthcare systems adopt lower-cost alternatives. Manufacturers must therefore depend on subcutaneous formulations, combination regimens, expanded indications, and next-generation antibody engineering to protect market share. This pricing shift may moderate revenue growth in established monoclonal antibody segments even as patient treatment volumes continue to rise.

 

Competitive Landscape—Portfolio Breadth and Delivery Scale Define Leadership

Johnson & Johnson—Multi-Platform Leadership Across CD38 and BCMA

Johnson & Johnson holds one of the strongest positions in the CD antigen cancer therapy market through its multiple myeloma portfolio. Darzalex and Darzalex Faspro target CD38, Carvykti targets BCMA through CAR-T technology, and Tecvayli redirects CD3-positive T cells toward BCMA-expressing myeloma cells. This coverage allows the company to participate across newly diagnosed, relapsed, and treatment-resistant patient populations.

Darzalex generated USD 3.54 billion in the second quarter of 2025, reflecting its widespread use in combination regimens and the growing adoption of its subcutaneous formulation. Carvykti extends the company into personalized cell therapy, while Tecvayli provides an immediately available bispecific alternative for eligible patients. This combination of a high-volume antibody franchise with rapidly expanding BCMA therapies gives Johnson & Johnson a broader commercial position than companies dependent on a single therapeutic modality.

Gilead Sciences/Kite Pharma—Manufacturing Scale Supports CD19 CAR-T Leadership

Gilead Sciences, through Kite Pharma, maintains a leading position in CD19-directed cellular therapy with Yescarta and Tecartus. Yescarta is used across large B-cell and follicular lymphomas, while Tecartus addresses mantle cell lymphoma and adult B-cell acute lymphoblastic leukemia. The portfolio benefits from an established manufacturing network, certified treatment centers, and clinical experience across several B-cell malignancies.

Gilead reported USD 1.8 billion in cell-therapy sales during 2025. Yescarta generated approximately USD 1.5 billion, while Tecartus recorded USD 344 million. However, total cell-therapy revenue declined by 7% year-over-year, indicating stronger competition from alternative CAR-T products, bispecific antibodies, and expanded treatment options. Gilead’s future position will depend on improving manufacturing turnaround, widening international access, and developing next-generation cellular therapies with stronger persistence and broader antigen coverage.

Other Companies Expanding the CD-Directed Treatment Ecosystem

• Roche/Genentech: Maintains a broad CD20 franchise through Rituxan/MabThera and Gazyva while expanding into CD20×CD3 bispecific antibodies through Lunsumio and Columvi.

• Bristol Myers Squibb: Competes in cellular therapy through the CD19-directed Breyanzi and BCMA-directed Abecma, covering lymphoma, leukemia, and multiple myeloma.

• Novartis: Commercialized Kymriah, the first FDA-approved CAR-T therapy, and remains active in CD19-directed cellular therapy for leukemia and lymphoma.

• Amgen: Holds an important position in bispecific therapy through Blincyto, a CD19×CD3 BiTE used in B-cell precursor acute lymphoblastic leukemia.

• Genmab and AbbVie: Jointly commercialize Epkinly, a subcutaneous CD20×CD3 bispecific antibody used in relapsed or refractory B-cell lymphomas.

• Pfizer: Participates through Elrexfio, a BCMA×CD3 bispecific antibody for multiple myeloma, and Besponsa, a CD22-directed antibody-drug conjugate for B-cell acute lymphoblastic leukemia.

• Sanofi: Competes in the CD38 multiple myeloma segment through Sarclisa, which is used in combination with established anti-myeloma regimens.

• Regeneron Pharmaceuticals: Expands the BCMA bispecific category through Lynozyfic, an off-the-shelf treatment for heavily pretreated multiple myeloma.

• Autolus Therapeutics: Entered the commercial CAR-T market with Aucatzyl, a CD19-directed therapy approved for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

• Legend Biotech: Co-developed Carvykti with Johnson & Johnson and contributes BCMA-directed CAR-T research, manufacturing expertise, and international commercialization support.

• Takeda: Participates through Adcetris, a CD30-directed antibody-drug conjugate used across classical Hodgkin lymphoma and selected T-cell lymphomas.

• AstraZeneca: Strengthens its hematologic oncology pipeline through antibody engineering, cell-therapy research, and combination strategies targeting resistant blood cancers.

 

Analyst Commentary—Platform Diversity and Delivery Speed Will Shape Future Leadership

The CD antigen cancer therapy market is shifting from single-target therapies toward diversified antigen platforms, with growth increasingly concentrated in BCMA-directed CAR-T therapies and CD3-engaging bispecific antibodies. While CD38 remains the largest revenue-generating target (32% share; USD 10.560 billion in 2025), BCMA is emerging as the key growth driver supported by expanding multiple myeloma treatment options. The competitive landscape is moving beyond antibody commercialization toward faster manufacturing, off-the-shelf therapies, dual-target approaches, and solutions for antigen escape.

 

CD Antigen Cancer Therapy Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 33.0 Billion
Revenue Forecast in 2032	USD 66.3 Billion
Overall Growth Rate	CAGR of 10.85% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Target Antigen, By Therapeutic Modality, By Cancer Application, By End User, By Geography
By Target Antigen	CD38, CD19, CD20, BCMA/CD269, CD22, CD30, CD33, CD70, and Other Targets
By Therapeutic Modality	Monoclonal Antibodies, CAR-T Cell Therapies, Antibody-Drug Conjugates, Bispecific Antibodies and BiTEs, Radioimmunotherapies, Immunotoxins, and Other Modalities
By Cancer Application	Multiple Myeloma, B-Cell Lymphomas, Leukemias, Hodgkin Lymphoma and Other Cancers
By End User	Hospitals and Comprehensive Cancer Centers, Specialty Hematology and Cell-Therapy Centers, Research and Academic Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising cancer prevalence, improved treatment outcomes, increasing antigen coverage, expansion of CD19- and BCMA-directed CAR-T therapies, wider availability of targeted immunotherapies, and movement toward earlier treatment settings
Customization Option	Available upon request